Beigene Ltd (BGNE.OQ)
126.61USD
24 May 2019
$-1.73 (-1.35%)
$128.34
$128.82
$130.51
$126.33
69,143
97,923
$220.09
$105.19
Latest Key Developments (Source: Significant Developments)
Beigene Posts Qtrly Net Loss Attributable Of $167.6 Million
May 10 (Reuters) - Beigene Ltd <6160.HK>::QTRLY NET LOSS ATTRIBUTABLE TO BEIGENE, LTD. $167.6 MILLION VERSUS LOSS OF $104.6 MILLION.QTRLY TOTAL REVENUES $77.8 MILLION VERSUS $32.5 MILLION. Full Article
BeiGene Q1 Loss Per Share $0.22
May 9 (Reuters) - Beigene Ltd <6160.HK>::BEIGENE REPORTS FIRST QUARTER 2019 FINANCIAL RESULTS.Q1 LOSS PER SHARE $0.22.COLLABORATION REVENUE TOTALED $20.41 MILLION FOR Q1 ENDED MARCH 31, 2019, COMPARED TO $9.29 MILLION FOR SAME PERIOD IN 2018.QTRLY LOSS PER SHARE $0.22. Full Article
Beigene Ltd Says CEO's Total Compensation For FY 2018 Was $27.9 Mln Versus $10.3 Mln In FY 2017
April 29 (Reuters) - Beigene Ltd <6160.HK>::BEIGENE LTD SAYS CEO JOHN V. OYLER'S TOTAL COMPENSATION FOR FY 2018 WAS $27.9 MILLION VERSUS $10.3 MILLION IN FY 2017- SEC FILING.BEIGENE LTD SAYS GENERAL MANAGER OF CHINA AND PRESIDENT XIAOBIN WU'S TOTAL COMPENSATION FOR FY 2018 WAS $21.5 MILLION.BEIGENE LTD - RATIO OF 2018 ANNUAL TOTAL COMPENSATION OF CEO TO MEDIAN OF ANNUAL TOTAL COMPENSATION OF ALL EMPLOYEES IS 135:1. Full Article
Bioatla And Beigene Form Worldwide Collaboration To Develop And Commercialize Novel Conditionally Active Biologic Ctla-4 Therapy
April 9 (Reuters) - Beigene Ltd <6160.HK>::BIOATLA AND BEIGENE FORM WORLDWIDE COLLABORATION TO DEVELOP AND COMMERCIALIZE NOVEL CONDITIONALLY ACTIVE BIOLOGIC CTLA-4 THERAPY.BIOATLA LLC - WILL RECEIVE AN UPFRONT PAYMENT OF $20 MILLION AND A MILESTONE PAYMENT UPON REACHING DEFINED EARLY CLINICAL OBJECTIVES.BIOATLA - BEIGENE WILL HOLD A CO-EXCLUSIVE LICENSE WITH BIOATLA TO DEVELOP AND MANUFACTURE PRODUCT CANDIDATE GLOBALLY.BIOATLA - IS ALSO ELIGIBLE TO RECEIVE UP TO $249 MILLION IN MILESTONE PAYMENTS. Full Article
Beigene Reports Qtrly Loss Per Share Of $0.35
Feb 27 (Reuters) - Beigene Ltd <6160.HK>::BEIGENE REPORTS FOURTH QUARTER AND FULL YEAR 2018 FINANCIAL RESULTS.BEIGENE LTD QTRLY NET LOSS PER ADS ATTRIBUTABLE TO BEIGENE LTD $4.52.BEIGENE LTD QTRLY LOSS PER SHARE $0.35.BEIGENE LTD QTRLY TOTAL REVENUES $58.67 MILLION VERSUS $18.17 MILLION. Full Article
Hillhouse Capital Management Ltd Reports 1.7 Pct Stake In Beigene Ltd
Jan 3 (Reuters) - Beigene Ltd <6160.HK>::HILLHOUSE CAPITAL MANAGEMENT, LTD. REPORTS 1.7 PERCENT STAKE IN BEIGENE LTD AS OF JANUARY 1 - SEC FILING.HILLHOUSE CAPITAL MANAGEMENT, LTD. PREVIOUSLY REPORTED 9.29 PERCENT STAKE IN BEIGENE LTD AS OF FEBRUARY 8, 2016. Full Article
Zymeworks, Beigene Announce License And Collaboration Agreement For Zymeworks' Her2-Targeted Therapeutic Candidates
Nov 27 (Reuters) - Beigene Ltd <6160.HK>::ZYMEWORKS AND BEIGENE ANNOUNCE LICENSE AND COLLABORATION AGREEMENT FOR ZYMEWORKS’ HER2-TARGETED THERAPEUTIC CANDIDATES, ZW25 AND ZW49, IN ASIA-PACIFIC AND RESEARCH AND LICENSE AGREEMENT FOR ZYMEWORKS’ AZYMETRIC™ AND EFECT™ PLATFORMS GLOBALLY.ZYMEWORKS INC - ZYMEWORKS WILL RECEIVE TOTAL UPFRONT PAYMENTS OF US$40 MILLION UNDER ZW25 AND ZW49 AGREEMENTS AND US$20 MILLION UNDER PLATFORM AGREEMENT.ZYMEWORKS INC - BEIGENE ACQUIRES EXCLUSIVE DEVELOPMENT AND COMMERCIAL RIGHTS TO ZYMEWORKS' BISPECIFIC CANDIDATES, ZW25 AND ZW49, IN ASIA.ZYMEWORKS INC - BEIGENE ALSO ACQUIRES LICENSES FOR ZYMEWORKS' AZYMETRIC AND EFECT PLATFORMS.ZYMEWORKS INC - BEIGENE ACQUIRES EXCLUSIVE RIGHTS TO ZW25 AND ZW49, IN ASIA (EXCLUDING JAPAN), AUSTRALIA, AND NEW ZEALAND.ZYMEWORKS INC - ZYMEWORKS ELIGIBLE TO RECEIVE DEVELOPMENT AND COMMERCIAL MILESTONE PAYMENTS PLUS POTENTIAL ROYALTIES ON PRODUCT SALES..ZYMEWORKS - IS ELIGIBLE TO RECEIVE UP TO US$390 MILLION IN DEVELOPMENT AND COMMERCIAL MILESTONE PAYMENTS FOR BOTH PRODUCT CANDIDATES.ZYMEWORKS - UNDER TERMS OF AGREEMENT FOR AZYMETRIC AND EFECT PLATFORMS, CO ELIGIBLE TO RECEIVE UP TO AN AGGREGATE OF US$702 MILLION IN MILESTONE PAYMENTS.ZYMEWORKS - ELIGIBLE TO GET UPTO $702 MILLION IN DEVELOPMENT & COMMERCIAL MILESTONE PAYMENTS FOR UP TO 3 BISPECIFIC PRODUCT CANDIDATES DEVELOPED. Full Article
Beigene Reports Quarterly Total Revenues Of $54.2 Million
Nov 8 (Reuters) - Beigene Ltd <6160.HK>::QTRLY TOTAL REVENUES $54.2 MILLION VERSUS $220.2 MILLION.QTRLY NET LOSS ATTRIBUTABLE WAS $144 MILLION VERSUS PROFIT OF $117.4 MILLION. Full Article
Beigene Initiates Global Head-To-Head Phase 3 Clinical Trial Of Zanubrutinib
Nov 8 (Reuters) - Beigene Ltd <6160.HK>::BEIGENE INITIATES GLOBAL HEAD-TO-HEAD PHASE 3 CLINICAL TRIAL OF ZANUBRUTINIB. Full Article
Beigene Announces Updated Results From Phase 1 Clinical Trial Of Zanubrutinib
Oct 12 (Reuters) - Beigene Ltd <6160.HK>::BEIGENE ANNOUNCES UPDATED RESULTS FROM PHASE 1 CLINICAL TRIAL OF ZANUBRUTINIB IN PATIENTS WITH WALDENSTRÖM’S MACROGLOBULINEMIA.BEIGENE LTD - FIRST U.S. NDA FILING FOR ZANUBRUTINIB EXPECTED TO FILE IN FIRST HALF OF 2019.BEIGENE LTD - TREATMENT WITH ZANUBRUTINIB WAS GENERALLY WELL-TOLERATED & MAJORITY OF ADVERSE EVENTS WERE GRADE 1 OR 2 IN SEVERITY.BEIGENE LTD - UPDATED RESULTS FROM STUDY INCLUDED THAT OVERALL RESPONSE RATE WAS 92 PERCENT.BEIGENE LTD - 4 PATIENTS DISCONTINUED STUDY TREATMENT DUE TO DISEASE PROGRESSION & 1 PATIENT REMAINS ON TREATMENT POST-DISEASE PROGRESSION.BEIGENE - UPDATED STUDY RESULTS INCLUDED NINE PATIENTS DISCONTINUED DUE TO AES. Full Article
UPDATE 2-Shanghai Junshi Biosciences soars on HK debut after $394 mln IPO
* Junshi Biosciences taking advantage of new listing rules in HK
Earnings vs. 
Estimates